How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

691 results for

Seborrheic Dermatitis

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

1. Pimecrolimus for the Treatment of Adults with Atopic Dermatitis, Seborrheic Dermatitis, or Psoriasis: A Review of Clinical and Cost-Effectiveness

Pimecrolimus for the Treatment of Adults with Atopic Dermatitis, Seborrheic Dermatitis, or Psoriasis: A Review of Clinical and Cost-Effectiveness Pimecrolimus for the Treatment of Adults with Atopic Dermatitis, Seborrheic Dermatitis, or Psoriasis: A Review of Clinical and Cost-Effectiveness | CADTH.ca Find the information you need Pimecrolimus for the Treatment of Adults with Atopic Dermatitis, Seborrheic Dermatitis, or Psoriasis: A Review of Clinical and Cost-Effectiveness Pimecrolimus (...) for the Treatment of Adults with Atopic Dermatitis, Seborrheic Dermatitis, or Psoriasis: A Review of Clinical and Cost-Effectiveness Published on: September 25, 2017 Project Number: RC0919-000 Product Line: Research Type: Drug Report Type: Summary with Critical Appraisal Result type: Report Question What is the clinical effectiveness of pimecrolimus for the treatment of adults with atopic dermatitis? What is the clinical effectiveness of pimecrolimus for the treatment of adults with seborrheic dermatitis? What

2017 Canadian Agency for Drugs and Technologies in Health - Rapid Review

4. Topical Application of 5-Fluorouracil Associated with Distant Seborrheic Dermatitis-like Eruption: Case Report and Review of Seborrheic Dermatitis Cutaneous Reactions after Systemic or Topical Treatment with 5-Fluorouracil (PubMed)

Topical Application of 5-Fluorouracil Associated with Distant Seborrheic Dermatitis-like Eruption: Case Report and Review of Seborrheic Dermatitis Cutaneous Reactions after Systemic or Topical Treatment with 5-Fluorouracil 5-Fluorouracil is a fluoropyrimidine antineoplastic medication that is used to topically treat actinic keratoses. Although local adverse effects to the drug are common and anticipated, distant skin reactions are rare and unexpected. In this case report, we describe a patient (...) who developed seborrheic dermatitis-like eruption at a distant site after topical application of 5-fluorouracil to his arms.A 63-year-old man with actinic keratoses on his arms developed a facial seborrheic dermatitis-like reaction after topically applying 5-fluorouracil 5% cream twice daily to actinic keratoses on his forearms for 7 days. The facial dermatosis resolved shortly after discontinuation of the 5-fluorouracil; upon rechallenge of topical 5-fluorouracil on his arms, the facial

Full Text available with Trip Pro

2018 Dermatology and therapy

5. Seborrheic dermatitis-Looking beyond Malassezia. (PubMed)

Seborrheic dermatitis-Looking beyond Malassezia. Seborrhoeic Dermatitis (SD) is a very common chronic and/or relapsing inflammatory skin disorder whose pathophysiology remains poorly understood. Yeast of the genus Malassezia has long been regarded as a main predisposing factor, even though causal relationship has not been firmly established. Additional predisposing factors have been described, including sebaceous activity, host immunity (especially HIV infection), epidermal barrier integrity

2019 Experimental Dermatology

6. Hydrocortisone 1% cream and sertaconazole 2% cream to treat facial seborrheic dermatitis: A double-blind, randomized clinical trial (PubMed)

Hydrocortisone 1% cream and sertaconazole 2% cream to treat facial seborrheic dermatitis: A double-blind, randomized clinical trial Seborrheic dermatitis (SD) is a chronic dermatitis with periods of remission and relapse that requires long-term treatment.We compared the efficacy and safety of treatment with sertaconazole with standard corticosteroid medications in adults with facial SD.In this double-blind, randomized controlled trial, 60 patients with a diagnosis of SD were enrolled. Patients

Full Text available with Trip Pro

2016 International journal of women's dermatology

7. Comparison of different regimens of pimecrolimus 1% cream in the treatment of facial seborrheic dermatitis. (PubMed)

Comparison of different regimens of pimecrolimus 1% cream in the treatment of facial seborrheic dermatitis. Pimecrolimus 1% cream has already been proved to be an effective and safe alternative to treat seborrheic dermatitis. However, the treatment periods were inconstant in previous studies.To evaluate the comparative efficacy of pimecrolimus 1% cream with different regimens for the treatment of facial seborrheic dermatitis.Thirty patients with facial seborrheic dermatitis were enrolled (...) be applied twice a day for 4 weeks to treat seborrheic dermatitis.© 2017 Wiley Periodicals, Inc.

Full Text available with Trip Pro

2018 Journal of cosmetic dermatology

8. Malassezia species retrieved from skin with pityriasis versicolor, seborrheic dermatitis and skin free of lesions: a comparison of two sampling methods. (PubMed)

Malassezia species retrieved from skin with pityriasis versicolor, seborrheic dermatitis and skin free of lesions: a comparison of two sampling methods. 29505089 2018 08 24 1365-2133 179 2 2018 Aug The British journal of dermatology Br. J. Dermatol. Malassezia species retrieved from skin with pityriasis versicolor, seborrhoeic dermatitis and skin free of lesions: a comparison of two sampling methods. 526-527 10.1111/bjd.16521 Pedrosa A F AF http://orcid.org/0000-0001-5969-0235 Division

2018 British Journal of Dermatology

9. Staphylococcus aureus is the most common bacterial agent of the skin flora of patients with seborrheic dermatitis (PubMed)

Staphylococcus aureus is the most common bacterial agent of the skin flora of patients with seborrheic dermatitis Seborrheic dermatitis is an inflammatory skin disease that affects 1-3% of the general population. The Malassezia species has been implicated as the main causative agent; however, the bacterial flora of the skin may also play role in the etiopathogenesis. Therefore, we investigated the most common bacterial agent of the skin flora of patients with seborrheic dermatitis.Fifty-one (...) patients with seborrheic dermatitis and 50 healthy individuals are included in this study. Sterile cotton swabs were rubbed on the scalp of the participants for bacterial culture. Colonial morphology was identified with gram stain and catalase test.Staphylococcus aureus was isolated from 25 (49%) patients with seborrheic dermatitis and 10 (20%) healthy individuals within the control group. Coagulase-negative staphylococci were isolated from 24 (47.1%) patients with seborrheic dermatitis and 17 (34

Full Text available with Trip Pro

2018 Dermatology practical & conceptual

10. Scalp Seborrheic Dermatitis and Dandruff Therapy Using a Herbal and Zinc Pyrithione-based Therapy of Shampoo and Scalp Lotion (PubMed)

Scalp Seborrheic Dermatitis and Dandruff Therapy Using a Herbal and Zinc Pyrithione-based Therapy of Shampoo and Scalp Lotion Objective: The aim of this study was to evaluate the safety and efficacy of an herbal and zinc pyrithione shampoo and a scalp lotion (Kamedis Derma-Scalp Dandruff Therapy, Kamedis Ltd., Tel Aviv, Israel) for the treatment of scalp seborrheic dermatitis and dandruff. Design: This was an interventional, open-label, safety and efficacy study. Setting: This open-label study (...) was conducted at Consumer Product Testing Company Inc. in Fairfield, New Jersey. At the baseline visit (Day 0), an examination of the scalp was conducted by a board-certified dermatologist. The entire scalp was evaluated for evidence of seborrheic dermatitis using the Adherent Scalp Flaking Score with a 10-point scale. Only subjects with evidence of moderate-to-greater seborrheic dermatitis or moderate-to-greater dandruff were deemed qualified for inclusion in the study. Participants: Fifty subjects were

Full Text available with Trip Pro

2018 The Journal of clinical and aesthetic dermatology

11. Progressive Facial Papules in an African-American Patient: An Atypical Presentation of Seborrheic Dermatitis (PubMed)

Progressive Facial Papules in an African-American Patient: An Atypical Presentation of Seborrheic Dermatitis This case report highlights a unique variant of seborrheic dermatitis (SD) in a 30-year-old African-American woman with progressive facial papules. Four weeks of uninterrupted mild potency topical corticosteroid therapy produced marked improvement of signs and symptoms of biopsy-confirmed SD. SD mimicking cutaneous sarcoidosis is a unique treatment-responsive variant of SD that may

Full Text available with Trip Pro

2018 The Journal of clinical and aesthetic dermatology

12. A Proof of Concept Clinical Trial Evaluating the Safety and Efficacy of Eucrisa (Crisaborole) in Patients With Seborrheic Dermatitis

A Proof of Concept Clinical Trial Evaluating the Safety and Efficacy of Eucrisa (Crisaborole) in Patients With Seborrheic Dermatitis A Proof of Concept Clinical Trial Evaluating the Safety and Efficacy of Eucrisa (Crisaborole) in Patients With Seborrheic Dermatitis - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You (...) have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. A Proof of Concept Clinical Trial Evaluating the Safety and Efficacy of Eucrisa (Crisaborole) in Patients With Seborrheic Dermatitis The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. of clinical studies and talk to your health care provider before

2018 Clinical Trials

13. Omiganan Twice a Day (BID) in Patients With Facial Seborrheic Dermatitis

Omiganan Twice a Day (BID) in Patients With Facial Seborrheic Dermatitis Omiganan Twice a Day (BID) in Patients With Facial Seborrheic Dermatitis - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Omiganan (...) Twice a Day (BID) in Patients With Facial Seborrheic Dermatitis The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. of clinical studies and talk to your health care provider before participating. Read our for details. ClinicalTrials.gov Identifier: NCT03688971 Recruitment Status : Recruiting First Posted : September 28, 2018 Last Update Posted : January 8

2018 Clinical Trials

14. Association between diet and seborrheic dermatitis: a cross-sectional study. (PubMed)

Association between diet and seborrheic dermatitis: a cross-sectional study. Current treatments for seborrheic dermatitis provide only temporary relief. Therefore, identifying modifiable lifestyle factors may help reduce disease burden. The objective of this study was to determine whether specific dietary patterns or total antioxidant capacity are associated with seborrheic dermatitis. Participants of the Rotterdam Study with a skin examination and a food frequency questionnaire were included (...) . Total antioxidant capacity was assessed on the basis of ferric reducing antioxidant potential of each food item. Dietary patterns were identified with principal component analysis (PCA). Multivariable logistic regression analyses were used to assess the association between total antioxidant capacity, dietary pattern-derived PCA factors, and seborrheic dermatitis adjusted for confounders. In total, 4,379 participants were included, of whom 636 (14.5%) had seborrheic dermatitis. The PCA identified

2018 Journal of Investigative Dermatology

15. Increased IL17-expressing γδ T Cells in Seborrheic Dermatitis-like Lesions of the Mpzl3 Knockout Mice. (PubMed)

Increased IL17-expressing γδ T Cells in Seborrheic Dermatitis-like Lesions of the Mpzl3 Knockout Mice. Seborrhoeic Dermatitis (SD) is a common inflammatory skin disorder, but its molecular pathogenesis remains elusive. Previously, we have established the Mpzl3 knockout (-/-) mice as a model for SD. In this study, we focused on early phases of skin inflammation and determined the cytokine profiles and identified immune cell types in the lesional skin in the Mpzl3 -/- mice. Using flow cytometry

2018 Experimental Dermatology

16. Treatment of Seborrheic Dermatitis: A Comprehensive Review. (PubMed)

Treatment of Seborrheic Dermatitis: A Comprehensive Review. Seborrheic dermatitis (SD) is a chronic, recurring inflammatory skin disorder that manifests as erythematous macules or plaques with varying levels of scaling associated with pruritus. The condition typically occurs as an inflammatory response to Malassezia species and tends to occur on seborrheic areas, such as the scalp, face, chest, back, axilla, and groin areas. SD treatment focuses on clearing signs of the disease; ameliorating

2018 Journal of Dermatological Treatment

17. The Genetic Basis of Seborrheic Dermatitis: A Review. (PubMed)

The Genetic Basis of Seborrheic Dermatitis: A Review. Seborrhoeic Dermatitis (SD) is a common inflammatory skin disease that presents as itchy, flaking skin in the seborrhoeic areas. Various environmental and intrinsic factors have been identified as predisposing factors for SD, but its aetiology remains poorly understood. Although it was recognized that genetic factors play a role in SD aetiology, there have not been studies that systematically review the literature specifically for causal

2017 Journal of the European Academy of Dermatology and Venereology

18. Prevalence and determinants of seborrheic dermatitis in a middle aged and elderly population: the Rotterdam Study. (PubMed)

Prevalence and determinants of seborrheic dermatitis in a middle aged and elderly population: the Rotterdam Study. Seborrhoeic dermatitis is a chronic relapsing inflammatory skin disease with unclear pathophysiological mechanisms.To establish which lifestyle and physiological determinants are associated with seborrhoeic dermatitis.Seborrhoeic dermatitis was diagnosed by a trained physician during a full-body skin examination within the Rotterdam Study, a prospective population-based cohort (...) study in middle-aged and elderly people. The current design is a comparative cross-sectional study embedded in the Rotterdam Study. Potential factors were identified from the literature and analysed in a multivariable logistic regression, including: age, sex, obesity, skin colour, stress, depression, education level, hypertension, climate, xerosis cutis, alcohol and tobacco use.Of the 5498 participants, 788 participants were diagnosed with seborrhoeic dermatitis (14·3%). We found associations

Full Text available with Trip Pro

2017 British Journal of Dermatology

19. Pilot Study for the Use of Photodynamic Therapy in the Treatment of Seborrheic Dermatitis

Pilot Study for the Use of Photodynamic Therapy in the Treatment of Seborrheic Dermatitis Pilot Study for the Use of Photodynamic Therapy in the Treatment of Seborrheic Dermatitis - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more (...) studies before adding more. Pilot Study for the Use of Photodynamic Therapy in the Treatment of Seborrheic Dermatitis The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT03114111 Recruitment Status : Active, not recruiting First Posted : April 14, 2017 Last Update Posted : October 9, 2018 Sponsor

2017 Clinical Trials

20. Treatment of Seborrheic Dermatitis Using a Novel Herbal-based Cream (PubMed)

Treatment of Seborrheic Dermatitis Using a Novel Herbal-based Cream Objective: Seborrheic dermatitis is a common relapsing inflammatory skin condition occurring in approximately 3 to 5 percent of the general population. Current available therapies control, but do not cure seborrhea. The study's objective was to determine the safety and efficacy of a barrier-based, nonsteroidal cream incorporating herbal extracts as a treatment for facial seborrheic dermatitis. Design: Interventional, open label (...) , safety/efficacy study. Setting: At the baseline visit, the investigator selected a target area on the face. The target area was evaluated for Investigator Static Global Assessment, desquamation (scaling), induration (inflammation), and erythema (redness) as well as self-assessed pruritus. Participants: Thirty-two subjects with seborrheic dermatitis were enrolled in the study. Measurements: Subjects were instructed to use the study medication twice a day, morning and evening, for a consecutive period

Full Text available with Trip Pro

2017 The Journal of clinical and aesthetic dermatology

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>